Mentlein R, Dahms P, Grandt D, Krüger R
Anatomisches Institut, Universität Kiel, Germany.
Regul Pept. 1993 Dec 10;49(2):133-44. doi: 10.1016/0167-0115(93)90435-b.
Neuropeptide Y, peptide YY and pancreatic polypeptide share an evolutionary conserved proline-rich N-terminal sequence, a structure generally known to be inert to the attack of common proteinases, but a potential target for specialized proline-specific aminopeptidases. Purified human dipeptidyl peptidase IV (also termed CD 26) liberated N-terminal Tyr-Pro from both, neuropeptide Y and peptide YY, with very high specific activities and Km values in the micromolar range, but almost no Ala-Pro from pancreatic polypeptide. Other proline-specific aminopeptidases exhibited low (aminopeptidase P, liberation of N-terminal Tyr) or totally no activity (dipeptidyl peptidase II), as was also observed with less-specific aminopeptidases (aminopeptidase M, leucine aminopeptidase). When human serum was incubated with neuropeptide Y or peptide YY at micro- and nanomolar concentrations, Tyr-Pro was detected as a metabolite of both peptides. Formation of Tyr-Pro in serum was blocked in the presence of Lys-pyrrolidine and diprotin A (Ile-Pro-Ile), specific, competitive inhibitors of dipeptidyl peptidase IV. Incubation of neuropeptide Y or peptide YY with immunocytochemically defined, cultivated endothelial cells from human umbilical cord also yielded Tyr-Pro. Dipeptidyl peptidase IV could be immunostained on most endothelial cells by a specific antibody. We suggest that dipeptidyl peptidase IV might be involved in the degradation of neuropeptide Y and peptide YY to N-terminal truncated neuropeptide Y(3-36) and peptide YY(3-36). Since specific binding to Y1, but not to Y2 subtype of neuropeptide Y/peptide YY receptors requires intact N- as well as C-termini of neuropeptide Y and peptide YY, removal of their amino-terminal dipeptides by dipeptidyl peptidase IV inactivates them for binding to one receptor subtype.
神经肽Y、肽YY和胰多肽具有进化上保守的富含脯氨酸的N端序列,该结构通常对常见蛋白酶的攻击呈惰性,但却是特定脯氨酸特异性氨肽酶的潜在作用靶点。纯化的人二肽基肽酶IV(也称为CD 26)能从神经肽Y和肽YY中释放出N端的酪氨酸-脯氨酸,具有非常高的比活性,其米氏常数在微摩尔范围内,但从胰多肽中几乎不释放丙氨酸-脯氨酸。其他脯氨酸特异性氨肽酶表现出低活性(氨肽酶P,释放N端酪氨酸)或完全无活性(二肽基肽酶II),非特异性氨肽酶(氨肽酶M、亮氨酸氨肽酶)也是如此。当人血清与微摩尔和纳摩尔浓度的神经肽Y或肽YY孵育时,酪氨酸-脯氨酸被检测为这两种肽的代谢产物。在存在赖氨酸-吡咯烷和二丙素A(异亮氨酸-脯氨酸-异亮氨酸)(二肽基肽酶IV的特异性竞争性抑制剂)的情况下,血清中酪氨酸-脯氨酸的形成被阻断。将神经肽Y或肽YY与人脐带来源的经免疫细胞化学鉴定的培养内皮细胞孵育也产生了酪氨酸-脯氨酸。二肽基肽酶IV可以被一种特异性抗体在大多数内皮细胞上免疫染色。我们认为二肽基肽酶IV可能参与将神经肽Y和肽YY降解为N端截短的神经肽Y(3-36)和肽YY(3-36)。由于神经肽Y/肽YY受体的Y1亚型(而非Y2亚型)的特异性结合需要神经肽Y和肽YY完整的N端和C端,二肽基肽酶IV去除它们的氨基端二肽会使其无法与一种受体亚型结合。